NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-18-846 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.
Funding Opportunity PAR-18-847 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.
Funding Opportunity PAR-18-848 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.
Notice NOT-HL-18-632 from the NIH Guide for Grants and Contracts
Notice NOT-DA-18-023 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-079 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-078 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-18-025 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory and developmental research projects to uncover functional roles of non-coding RNAs (ncRNAs) in viral infectious diseases. Importantly, the projects should focus on functional characterization and mechanistic studies of previously identified ncRNAs. Applications limited to the discovery or identification of ncRNAs will not be supported under this RFA.
Funding Opportunity RFA-AI-18-022 from the NIH Guide for Grants and Contracts. The Purpose of this Funding Opportunity Announcement is to solicit applications to rapidly implement early clinical trials using native and/or engineered monoclonal antibodies (mAbs) to achieve a drug-free sustained virologic remission in HIV infected individuals.
Funding Opportunity PA-18-842 from the NIH Guide for Grants and Contracts. The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide-ranging areas. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technical capabilities, and resource sets. Importantly, the supplemental proposal is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component.
Notice NOT-CA-18-088 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-841 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.
Notice NOT-HL-18-637 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-844 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All proposals should address how the methods would scale to address larger and larger data sets.
Funding Opportunity PAR-18-843 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All proposals should address how the methods would scale to address larger and larger data sets.
Funding Opportunity RFA-AG-19-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a phased innovation initiative to facilitate multi-omics/integrative approaches to identify omics profiles associated with protection against multiple aging conditions, with exceptional health span, and to refine strategies for utilizing these profiles for therapeutics development. Specifically, a phased innovation cooperative agreement mechanism (UH2/UH3) involving an interdisciplinary research team will be used to support a single project that will conduct integrative analysis of person -specific multiple omics measurements (e.g., transcriptomics, proteomics, metabolomics) generated across multiple tissues ; the multi-omic profiling should be conducted on individuals from extensively phenotyped cohorts with substantial numbers of long-lived individuals with characteristics of exceptionally healthy aging and appropriate controls. It will also: 1) harmonize and extend the use of existing phenotypic data from these studies to apply phenomics to transcriptomic, proteomic, metabolomic findings, 2) select animal model species or strains with varying life spans for comparative omics studies and identify potential determinants of species differences in longevity and rates of disease development, 3) develop appropriate computational and analytical tools to identify omics profiles associated with exceptional longevity and healthy aging, 4) apply translational bioinformatics approaches and leverage existing publicly available drug signatures databases to identify molecules that could produce profiles associated with exceptionally healthy aging and 5) exchange data with other NIH/NIA-supported related omics activities and other public-private partnerships (e.g., Trans-Omics for Precision Medicine (TOPMed), Accelerating Medicines Partnership- Alzheimers Disease (AMP-AD) for data harmonization and analysis.
Funding Opportunity RFA-RM-18-020 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to call for U24 cooperative agreement applications that will request funding to further develop and sustain up to three H3Africa Biorepositories, building upon existing infrastructure. The H3Africa Biorepositories will continue to have the responsibility of maintaining state of the art methods and technologies for DNA collection, processing, quality control, handling, management, and storage and of providing support services needed for bio-specimen collection and dissemination in Africa. They may also propose collection and handling of specimen types including but not limited to PBMCs, plasma, serum etc. Biorepositories will coordinate closely with H3Africa research projects and the H3Africa Bioinformatics network (H3ABioNet) to ensure responsible stewardship of high quality biological specimens linked to well-curated phenotypic and genomic data.
Notice NOT-RM-18-018 from the NIH Guide for Grants and Contracts
Notice NOT-AI-18-043 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-838 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on the fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through HPG, HPA, and HPT axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and IDDB.